BioDelivery Sciences to Report Fourth Quarter and Full Year 2020 Financial Results on March 10, 2021

Rhea-AI Summary

BioDelivery Sciences International (NASDAQ: BDSI) will report its Q4 and full-year 2020 financial results on March 10, 2021, before U.S. market open. A conference call will follow at 8:30 AM ET to discuss these results and update business operations. BDSI specializes in developing treatments for patients with chronic conditions, leveraging its proprietary BEMA® technology for chronic pain and opioid-induced constipation. Investors are encouraged to tune in for insights on the company’s performance and future outlook.

Positive

• Conference call scheduled for March 10, 2021, to discuss Q4 and full-year 2020 results.
• Company focuses on addressing unmet medical needs in chronic conditions.

Negative

• None.

RALEIGH, N.C., Feb. 17, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced that it will report its fourth quarter and full year 2020 financial results before the open of the U.S. financial markets on Wednesday, March 10, 2021. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations.

Conference Call Dial-In & Webcast Information:

Date:	Wednesday, March 10, 2021
Time:	8:30 AM Eastern Time
Domestic:	877-407-0789
International:	201-689-8562
Conference ID:	13715530
Webcast:	http://public.viavid.com/index.php?id=143193

About BioDelivery Sciences International, Inc.
BioDelivery Sciences International, Inc. (NASDAQ: BDSI) is a commercial-stage specialty pharmaceutical company dedicated to patients living with chronic conditions. BDSI has built a portfolio of products that includes utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA^®) technology to develop and commercialize, either on its own or in partnership with third parties, new applications of proven therapies aimed at addressing important unmet medical needs. BDSI's marketed products address serious and debilitating conditions, including chronic pain and opioid-induced constipation.

© 2021 BioDelivery Sciences International, Inc. All rights reserved.

Contact:
Bob Yedid
LifeSci Advisors
646-597-6989
Bob@LifeSciAdvisors.com

FAQ

When will BioDelivery Sciences report its Q4 2020 earnings?

BioDelivery Sciences will report its Q4 2020 earnings on March 10, 2021.

What time is the BioDelivery Sciences conference call?

The conference call is scheduled for 8:30 AM ET on March 10, 2021.

What is BDSI's primary focus in pharmaceutical development?

BDSI focuses on developing treatments for chronic pain and opioid-induced constipation using its BEMA® technology.

How can investors listen to the BioDelivery Sciences earnings call?

Investors can listen to the earnings call via the provided webcast link in the press release.